|
![]() |
![]() |
|||||||
| Supported by the Department for International Development, GlaxoSmithKline and the Bill & Melinda Gates Foundation | |||||||||
|
|||||||||
|
|
Defining
the cost of the Egyptian lymphatic filariasis elimination programme Impact
of two rounds of mass drug administration using diethylcarbamazine combined
with albendazole on the prevalence of Brugia timori and of intestinal
helminths on Alor Island, Indonesia Diethylcarbamazine
activity against Brugia malayi microfilariae is dependent on
inducible nitric-oxide synthase and the cyclooxygenase pathway Combined
Utilisation of Rapid Assessment Procedures for Loiasis (RAPLOA) and Onchocerciasis
(REA) in Rain forest Villages of Cameroon Frequent
detection of worm movements in onchocercal nodules by ultrasonography Homologs
of the Brugia malayi diagnostic antigen BmR1 are present in other filarial
parasites but induce different humoral immune responses Recombinant
antigen-based antibody assays for the diagnosis and surveillance of lymphatic
filariasis – a multicenter trial Comparison
of IgG4 assays using whole parasite extract and BmR1 recombinant antigen
in determining antibody prevalence in brugian filariasis Mapping
the distribution of Loa loa in Cameroon in support of the African
Programme for Onchocerciasis Control < Previous page | Next page > |
|
|||||||||||||||||||||||||||||
| |
||||||||||||||||||||||||||||||
| ©2006 Lymphatic Filariasis Support Centre |